Merck & Co., Inc. is looking to bring a new vaccine to market for the prevention of pneumococcal disease in adults, but the company will have to compete against Pfizer Inc., which has long been a rival in the market with its blockbuster Prevnar franchise. The company hopes the new vaccine could offer the broadest protection for adults.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?